isf 2405 has been researched along with dihydralazine in 2 studies
| Studies (isf 2405) | Trials (isf 2405) | Recent Studies (post-2010) (isf 2405) | Studies (dihydralazine) | Trials (dihydralazine) | Recent Studies (post-2010) (dihydralazine) |
|---|---|---|---|---|---|
| 9 | 1 | 0 | 416 | 62 | 18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nässberger, L | 1 |
| Andersson, M; Dahlbäck, B; Englund, G; Hanson, A | 1 |
2 other study(ies) available for isf 2405 and dihydralazine
| Article | Year |
|---|---|
The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence.
Topics: Antihypertensive Agents; Binding Sites; Dihydralazine; Dose-Response Relationship, Drug; Hydralazine; Luminescent Measurements; Magnetic Resonance Spectroscopy; Peroxidase; Pyridazines; Structure-Activity Relationship | 1991 |
Inhibition of complement components C3 and C4 by cadralazine and its active metabolite.
Topics: Antihypertensive Agents; Complement C3; Complement C4; Dihydralazine; Humans; Hydralazine; Hydroxylamine; Hydroxylamines; Procainamide; Pyridazines; Vasodilator Agents | 1991 |